Evaluation：A Phase I, Dose Escalation and Extension Study to Evaluate the Safety, Tolerability and Preliminary Effects of Oral BEL-X in Patients With Advanced Refractory Solid Malignancies
IND：US FDA (#127857) & Taiwan FDA
Trial site：National Taiwan University Hospital
National Cheng Kung University Hospital
Results：1. BEL-X showed safety and no serious side effects under the maximum tolerated dose of the subject.
2. It obtained significant effects on maintaining the body weight and quality of life of tested subjects.
Evaluation：A phase II adaptive design trial of BEL-X for HBeAg positive Chronic Hepatitis B
Status：File IND for US FDA and Taiwan FDA in 1st half of 2023
Start trial in 2023
Target：Rapidly enhance the HBe seroconversion rate
Strength of Product：1.High Quality, High Safety (Low toxicity and low side effects)
2.Global patent protectio
3.The Manufacturing and quality control of products followed by global regulations (PIC/S, cGMP)
Copyright (c) 2020 BELX Bio-Pharmaceutical (Taiwan) Corporation. All rights reserved